New anticoagulants - promising and failed developments

• Verfasst von: Harenberg, Job [VerfasserIn]
• Verfasst von: Hetjens, Svetlana [VerfasserIn]
• Verfasst von: Krejczy, Martin [VerfasserIn]
• Verfasst von: Wehling, Martin [VerfasserIn]
• Titel: New anticoagulants - promising and failed developments
• Verf.angabe: Job Harenberg, Svetlana Marx, Martin Krejczy and Martin Wehling
• Jahr: 2012
• Jahr des Originals: 2011
• Umfang: 10 S.
• Fussnoten: First published: 08 July 2011 ; Gesehen am 09.08.2018
• Titel Quelle: Enthalten in: British journal of pharmacology
• Ort Quelle: Malden, MA : Wiley, 1946
• Jahr Quelle: 2012
• Band/Heft Quelle: 165(2012), 2, Seite 363-372
• ISSN Quelle: 1476-5381
• DOI: doi:10.1111/j.1476-5381.2011.01578.x
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: anticoagulants
• Sach-SW: atrial fibrillation
• Sach-SW: factor Xa inhibitors
• Sach-SW: thrombin inhibitors
• K10plus-PPN: 1578428505

Abstract

New direct and indirect acting factor Xa (FXa) and thrombin inhibitors are being developed to overcome the downsides of the conventional anticoagulants - unfractionated and low molecular weight heparins and vitamin K antagonists. Ximelagatran and idraparinux failed to demonstrate an acceptable safety profile. Rivaroxaban and dabigatran are approved for the post-operative prevention of thromboembolic complications after elective hip or knee replacement surgery; dabigatran is approved for the prevention of embolism in patients with atrial fibrillation in an increasing number of countries. Several novel indirect antithrombin-dependent anticoagulants as well as antithrombin-independent oral direct FXa and thrombin inhibitors are investigated in multiple indications for the prophylaxis and treatment of venous thromboembolism and the prophylaxis of arterial thrombotic disorders. Quality-adjusted life years costs and incremental cost-effectiveness ratios are relatively high at present, but may decrease after approval of more new anticoagulants for additional indications.